Trial Profile

An Open-label, Phase 1, Single-dose Study to Evaluate the Pharmacokinetics of Elafibranor 120 mg in Adult Subjects With Hepatic Impairment and Adult Healthy Control Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elafibranor (Primary)
Indications Liver disorders; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
Focus Pharmacokinetics
Sponsors Genfit

15 Nov 2021 Results assessing effect of affects the pharmacokinetics, safety, and tolerability of elafibranor in hepatic impairment patients, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
02 Nov 2021 According to Genefit SA Media Release, data from this trial will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021
02 Nov 2021 Results published in the Genefit SA Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com